游说团体警告：特朗普药价提案恐致制药业损失1万亿美元

Core Viewpoint - The new drug pricing proposal by President Trump could lead to a loss of up to $1 trillion for pharmaceutical companies over the next decade, as it links drug prices in the Medicaid program to prices paid in foreign countries [1] Group 1: Industry Response - The pharmaceutical industry is no longer in a wait-and-see mode and is preparing for active lobbying efforts in response to the proposal [1] - Executives from the pharmaceutical sector are scheduled to visit Capitol Hill for discussions, indicating a heightened level of engagement [1] - The lobbying group PhRMA held an emergency conference call with board members to strategize against the proposal [1] Group 2: Legislative Context - The proposal requires House Republicans to link drug prices in the Medicaid program to foreign prices, which could result in significant revenue losses for drug manufacturers [1] - Some Republican lawmakers, including Brett Guthrie, have previously expressed opposition to the "international reference pricing" policy [2] - Guthrie is expected to meet with other Republicans to finalize decisions on Medicaid reform and related proposals [2] Group 3: Political Implications - Trump's previous actions and statements regarding drug pricing and manufacturing suggest a consistent approach towards lowering drug prices and reshoring production [2] - Joe Grogan, former chairman of the White House Domestic Policy Council, noted that Trump's commitment to these issues should not be surprising [2]